Malignant Glioma: Viewpoint—Chemotherapy
作者： Roger Stupp , Krisztian Homicsko , J. Gregory Cairncross
DOI: 10.1007/978-1-4614-8363-2_19
关键词:
摘要: Malignant gliomas are diffusely infiltrating and thus any local treatment has its inherent limitations. Alkylating agent chemotherapy repeatedly demonstrated improvement in disease-free overall survival. Concomitant chemoradiotherapy with temozolomide is the standard of care glioblastoma, neoadjuvant or adjuvant PCV improves survival anaplastic oligodendroglial tumors a 1p/19q co-deletion, however benefit only seen long follow-up > 6 years. Randomized trials glioma have shown that sequence, radiotherapy first at recurrence reverse, does not matter terms progression-free
springer.com
sci-hub.se 参考文章(126)
Masato Kochi, Isao Kitamura, Tomoaki Goto, Toru Nishi, Hideo Takeshima, Yoshiki Saito, Keizo Yamamoto, Takahiro Kimura, Takeshi Kino, Kenji Tada, Shoji Shiraishi, Shozaburo Uemura, Tazuko Iwasaki, Jun-ichi Kuratsu, Yukitaka Ushio, Randomized comparison of intra-arterial versus intravenous infusion of ACNU for newly diagnosed patients with glioblastoma Journal of Neuro-oncology. ,vol. 49, pp. 63- 70 ,(2000) , 10.1023/A:1006457502972
P. Kleihues, Webster K Cavenee, None, Pathology and genetics of tumours of the nervous system. International Agency for Research on Cancer. ,(2000)
Ch.J Vecht, M.J van den Bent, D Lacombe, EORTC Brain Tumor Group: achievements and perspectives. European Journal of Cancer. ,vol. 38, pp. 35- 38 ,(2002) , 10.1016/S0959-8049(01)00451-8
M. Brada, B. Baumert, Focal fractionated conformal stereotactic boost following conventional radiotherapy of high-grade gliomas: a randomized phase III study. A joint study of the EORTC (22972) and the MRC (BR10). Frontiers of Radiation Therapy and Oncology. ,vol. 33, pp. 241- 243 ,(1999) , 10.1159/000061233
Tomoyuki Koga, Keisuke Maruyama, Minoru Tanaka, Yasushi Ino, Nobuhito Saito, Keiichi Nakagawa, Junji Shibahara, Tomoki Todo, Extended field stereotactic radiosurgery for recurrent glioblastoma. Cancer. ,vol. 118, pp. 4193- 4200 ,(2012) , 10.1002/CNCR.27372
J. Ransohoff, C. B. Wilson, M. D. Walker, S. B. Green, D. P. Byar, J. T. Robertson, J. Mealey, W. R. Shapiro, R. G. Selker, T. A. Strike, W. H. Brooks, K. R. Smith, P. Paoletti, U. Batzdorf, G. L. Odom, D. A. Pistenmaa, W. E. Hunt, E. Alexander, Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer treatment reports. ,vol. 67, pp. 121- 132 ,(1983)
D. Osoba, M. Brada, W.K. A. Yung, M. Prados, Health-Related Quality of Life in Patients Treated With Temozolomide Versus Procarbazine for Recurrent Glioblastoma Multiforme Journal of Clinical Oncology. ,vol. 18, pp. 1481- 1491 ,(2000) , 10.1200/JCO.2000.18.7.1481
Eric T. Wong, Kenneth R. Hess, Mary Jo Gleason, Kurt A. Jaeckle, Athanassios P. Kyritsis, Michael D. Prados, Victor A. Levin, W.K. Alfred Yung, Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials Journal of Clinical Oncology. ,vol. 17, pp. 2572- 2578 ,(1999) , 10.1200/JCO.1999.17.8.2572
Henry S. Friedman, William P. Petros, Allan H. Friedman, Larry J. Schaaf, Tracy Kerby, Jennifer Lawyer, Mary Parry, Peter J. Houghton, Shelley Lovell, Karima Rasheed, Tim Cloughsey, Elizabeth S. Stewart, O. Michael Colvin, James M. Provenzale, Roger E. McLendon, Darell D. Bigner, Ilkcan Cokgor, Michael Haglund, Jeremy Rich, David Ashley, Joseph Malczyn, Gary L. Elfring, Langdon L. Miller, Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma Journal of Clinical Oncology. ,vol. 17, pp. 1516- 1525 ,(1999) , 10.1200/JCO.1999.17.5.1516
Harvey Kreisman, Norman Wolkove, Pulmonary toxicity of antineoplastic therapy. Seminars in Oncology. ,vol. 19, pp. 508- 520 ,(1992) , 10.5555/URI:PII:009377549290205F